For media-related inquiries, contact Mona Shater.
The latest updates and announcements from the USRDS below:
Legacy RenDER App Departure; New Application System in Place
The USRDS RenDER application has been replaced with a new application system entitled "Data Extraction System for Kidney Related Information & Basic Epidemiology, or DESKRIBE.
DESKRIBE allows users to retrieve information on the entire ESRD population or on precisely specified subgroups of interest. The system is designed to provide a high-level of interactivity and instant feedback, allowing users with varying background and knowledge to navigate the system.
In addition to the two previously existing applications on our website (ESRD Incident Count and ESRD Prevalent Count), two new modules have been added: the ESRD Hospitalization Rate and ESRD Mortality Rate. The ESRD Hospitalization tool can be used to display hospital admission and hospitalized days rate of ESRD patients. The ESRD Mortality Rate tool can be used to display morality rate of ESRD patients. Specific populations of interest and display formats can be tailored to the user's needs.
All modules currently part of DESKRIBE are in beta, and we welcome your feedback about the apps. Please send questions/comments to email@example.com.
ESRD Quarterly Update
The end-stage renal disease (ESRD) Quarterly Update with data through the second quarter of 2020 is now available.
USRDS Releases 2020 Interactive Annual Data Report
The Chronic Disease Research Group (CDRG), in partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is proud to announce the next evolution of the United States Renal Data System (USRDS) Annual Data Report (ADR): The 2020 interactive ADR. For the first time in the history of the USRDS, the ADR is fully interactive. Through intuitive, easy-to-use navigation, website users can sort through the volume chapters, customize data representation, and download the tailored information in common data formats.
“According to the recently published Global Burden of Disease in The Lancet, chronic kidney disease (CKD) has risen to the eighth leading cause of disability-adjusted life-years in people aged 50 to 74 years,” said Kirsten L. Johansen, MD, director of the USRDS Coordinating Center in Minneapolis, Minn. “As the United States population ages, the impact of chronic kidney disease and end-stage renal disease (ESRD) on health outcomes and health care spending cannot be overstated.”
Important findings in this year’s Annual Data Report include:
- A 14.9% prevalence of CKD among US adults
- A death rate more than twice as high in people with versus without CKD
- A 40% increase in hospitalizations with acute kidney injury from 2009 to 2018 and a persistently large disparity in acute kidney injury between Black and White patients
- An increase of only 0.2% in the adjusted rate of end-stage renal disease (ESRD) incidence from 2017 to 2018
- Strong growth in home dialysis use and preemptive kidney transplant
- A declining ultrafiltration rate in patients undergoing hemodialysis
- Lack of progress in catheter use at dialysis initiation, as well as hospitalization and readmission of dialysis patients, but a 1.5% decrease in the death rate of dialysis patients from 2017 to 2018
- All-time highs in kidney transplants and graft survival among deceased donor transplants
- Steadily decreasing use of prescription opioids among CKD and ESRD patients from 2009 to 2018
- 23.2% of Medicare fee-for-service spending in patients with CKD and ESRD and continued growth of Medicare Advantage enrollment of dialysis patients
The 2020 ADR also includes new content:
- A chapter devoted to the patient experience, including end-of-life care for patients with ESRD
- An unprecedented look at the impact of COVID-19 on death rates and hospitalizations in patients with ESRD, as well as the incidence of ESRD
“Compared to previous years, dialysis and kidney transplant patient mortality during the spring increased by 37% and 61%, respectively, while hospitalization for non-COVID-related reasons fell by 33%,” says Dr. Johansen. “Remarkably, the number of patients who were newly diagnosed with ESRD declined by almost 20%, illustrating the profound impact of COVID-19 on people with advanced CKD and ESRD.”
"The USRDS has been a critical system for kidney disease surveillance in the United States for more than 30 years," says Dr. Kevin C. Abbott, Director of the Kidney and Urology Epidemiology Program at NIDDK. "In tandem with the Advancing American Kidney Health initiative, this year's ADR represents the beginning of a new era, with interactive presentations of data about CKD and ESRD."
The USRDS serves the kidney community through research, analysis, and investigator-initiated research. If you have any questions about the new interactive ADR, please contact USRDS.
About the USRDS
The core purpose of the USRDS ADR is to characterize the impact of chronic kidney disease on the US population and to support research and policy initiatives designed to improve the care of individuals with kidney disease. The new report features data accumulated through 2018. Along with producing the ADR on end-stage renal disease and chronic kidney disease in the United States, the USRDS fulfills data requests, provides standard analysis files (SAFs) to researchers, produces the Researcher’s Guide to help researchers use USRDS data, and presents the results of its research at national conferences and in peer-reviewed journals. Learn more by visiting the USRDS website.
NIDDK research creates knowledge about and treatments for diseases that are among the most chronic, costly, and consequential for patients, their families, and the nation. Learn more by visiting the NIDDK website.
Now Live: New and Improved USRDS Website
The United States Renal Data System (USRDS) is proud to announce an expansive redesign of our website.
The redesigned website will provide the kidney community with a streamlined approach to the information that health care professionals, patients, and researchers seek. Updates include sleek, simple website navigation with easy access to the information users visit our website for the most: the Annual Data Report (ADR) and previous ADRs, end-stage renal disease (ESRD) quarterly updates, Standard Analysis File (SAF) requests, simple data requests, and much more.
The USRDS has also expanded its public use tools that are available to researchers. We are developing a new data query system that allows substantial customization by the user. Beta versions of this system for identifying counts of incident and prevalent ESRD patients—with resolution as fine as the county—are now available.
We look forward to continuing to serve the kidney community through research, analysis, and investigator-initiated research. If you have any questions about our website, please contact us.
ESRD Quarterly Update
The end-stage renal disease (ESRD) Quarterly Update with data through the third quarter of 2019 is now available.
2019 SAF Available
We identified an issue with the 2012 Institutional ESRD claims. The file didn't include the claims across the first service date for 2012 incident ESRD patients. If your study was approved to use this file, you can contact us to receive an update on the 2012 institutional claims.
Now Available: 2019 ADR
The abbreviated 2019 USRDS Annual Data Report is now available.
The RenDER system now includes data through 2016.
ESRD Update Available
The ESRD Quarterly Update with data through the third quarter of 2018 is now available.